Cargando…
Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
INTRODUCTION: The level of the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer’s disease (AD) and thus may serve as an outcome measure in clinical trials and facilitate earlier disease detection. METHODS: W...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333489/ https://www.ncbi.nlm.nih.gov/pubmed/30321501 http://dx.doi.org/10.1016/j.jalz.2018.08.006 |
_version_ | 1783387565673414656 |
---|---|
author | Sandelius, Åsa Portelius, Erik Källén, Åsa Zetterberg, Henrik Rot, Uros Olsson, Bob Toledo, Jon B. Shaw, Leslie M. Lee, Virginia M. Y. Irwin, David J. Grossman, Murray Weintraub, Daniel Chen-Plotkin, Alice Wolk, David A. McCluskey, Leo Elman, Lauren Kostanjevecki, Vesna Vandijck, Manu McBride, Jennifer Trojanowski, John Q. Blennow, Kaj |
author_facet | Sandelius, Åsa Portelius, Erik Källén, Åsa Zetterberg, Henrik Rot, Uros Olsson, Bob Toledo, Jon B. Shaw, Leslie M. Lee, Virginia M. Y. Irwin, David J. Grossman, Murray Weintraub, Daniel Chen-Plotkin, Alice Wolk, David A. McCluskey, Leo Elman, Lauren Kostanjevecki, Vesna Vandijck, Manu McBride, Jennifer Trojanowski, John Q. Blennow, Kaj |
author_sort | Sandelius, Åsa |
collection | PubMed |
description | INTRODUCTION: The level of the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer’s disease (AD) and thus may serve as an outcome measure in clinical trials and facilitate earlier disease detection. METHODS: We developed an enzyme-linked immunosorbent assay for CSF GAP-43 and measured healthy controls (n = 43), patients with AD (n = 275), or patients with other neurodegenerative diseases (n = 344). In a subpopulation (n = 93), CSF GAP-43 concentrations from neuropathologically confirmed cases were related to Aβ plaques, tau, α-synuclein, and TDP-43 pathologies. RESULTS: GAP-43 was significantly increased in AD compared to controls and most neurodegenerative diseases and correlated with the magnitude of neurofibrillary tangles and Aβ plaques in the hippocampus, amygdala, and cortex. GAP-43 was not associated to α-synuclein or TDP-43 pathology. DISCUSSION: The presynaptic marker GAP-43 is associated with both diagnosis and neuropathology of AD and thus may be useful as a sensitive and specific biomarker for clinical research. |
format | Online Article Text |
id | pubmed-6333489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-63334892020-01-01 Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology Sandelius, Åsa Portelius, Erik Källén, Åsa Zetterberg, Henrik Rot, Uros Olsson, Bob Toledo, Jon B. Shaw, Leslie M. Lee, Virginia M. Y. Irwin, David J. Grossman, Murray Weintraub, Daniel Chen-Plotkin, Alice Wolk, David A. McCluskey, Leo Elman, Lauren Kostanjevecki, Vesna Vandijck, Manu McBride, Jennifer Trojanowski, John Q. Blennow, Kaj Alzheimers Dement Article INTRODUCTION: The level of the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer’s disease (AD) and thus may serve as an outcome measure in clinical trials and facilitate earlier disease detection. METHODS: We developed an enzyme-linked immunosorbent assay for CSF GAP-43 and measured healthy controls (n = 43), patients with AD (n = 275), or patients with other neurodegenerative diseases (n = 344). In a subpopulation (n = 93), CSF GAP-43 concentrations from neuropathologically confirmed cases were related to Aβ plaques, tau, α-synuclein, and TDP-43 pathologies. RESULTS: GAP-43 was significantly increased in AD compared to controls and most neurodegenerative diseases and correlated with the magnitude of neurofibrillary tangles and Aβ plaques in the hippocampus, amygdala, and cortex. GAP-43 was not associated to α-synuclein or TDP-43 pathology. DISCUSSION: The presynaptic marker GAP-43 is associated with both diagnosis and neuropathology of AD and thus may be useful as a sensitive and specific biomarker for clinical research. 2018-10-12 2019-01 /pmc/articles/PMC6333489/ /pubmed/30321501 http://dx.doi.org/10.1016/j.jalz.2018.08.006 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license. |
spellingShingle | Article Sandelius, Åsa Portelius, Erik Källén, Åsa Zetterberg, Henrik Rot, Uros Olsson, Bob Toledo, Jon B. Shaw, Leslie M. Lee, Virginia M. Y. Irwin, David J. Grossman, Murray Weintraub, Daniel Chen-Plotkin, Alice Wolk, David A. McCluskey, Leo Elman, Lauren Kostanjevecki, Vesna Vandijck, Manu McBride, Jennifer Trojanowski, John Q. Blennow, Kaj Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology |
title | Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology |
title_full | Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology |
title_fullStr | Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology |
title_full_unstemmed | Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology |
title_short | Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology |
title_sort | elevated csf gap-43 is alzheimer’s disease specific and associated with tau and amyloid pathology |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333489/ https://www.ncbi.nlm.nih.gov/pubmed/30321501 http://dx.doi.org/10.1016/j.jalz.2018.08.006 |
work_keys_str_mv | AT sandeliusasa elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT porteliuserik elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT kallenasa elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT zetterberghenrik elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT roturos elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT olssonbob elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT toledojonb elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT shawlesliem elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT leevirginiamy elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT irwindavidj elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT grossmanmurray elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT weintraubdaniel elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT chenplotkinalice elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT wolkdavida elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT mccluskeyleo elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT elmanlauren elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT kostanjeveckivesna elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT vandijckmanu elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT mcbridejennifer elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT trojanowskijohnq elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology AT blennowkaj elevatedcsfgap43isalzheimersdiseasespecificandassociatedwithtauandamyloidpathology |